NCT00408447View on ClinicalTrials.gov

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Sickle Cell DiseaseBeta Thalassemia
Interventions
DRUG

Busulfan

Busulfan 4 mg/kg/d x 4d

DRUG

Fludarabine

Fludarabine 30 mg/m2/d x 6d

DRUG

Alemtuzumab

Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d

PROCEDURE

Allogeneic stem cell transplant

Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.

Trial Locations (1)

10032

Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University, New York

All Listed Sponsors
lead

Columbia University

OTHER